Parainflammation in the Ocular System: Considerations on the Underlying Mechanisms and Treatment of Dry Eye Disease
- PMID: 40156711
- PMCID: PMC12006601
- DOI: 10.1007/s40123-025-01115-0
Parainflammation in the Ocular System: Considerations on the Underlying Mechanisms and Treatment of Dry Eye Disease
Abstract
Introduction: The transition from regulated to dysregulated parainflammation is a new concept that needs to be elucidated to clarify the pathogenesis of dry eye disease (DED). This review summarizes the recent evidence about mechanisms that could lead to dysregulated parainflammation, proposing a new hypothesis to correlate this process with the progression to chronic inflammation.
Methods: A group of European experts on DED participated in a roundtable to discuss the role of parainflammation in the most common ocular diseases with regard to DED. Starting from the roundtable contents, a narrative review was conducted through a PubMed search based on the main topics discussed, namely: parainflammation, dysfunctional parainflammation, tear film lipid and mucin alterations, and tear cortisol.
Results: Parainflammation is involved in different ocular pathologies and is characterized by the involvement of the immune system and complement factors. In DED, continuous and persistent insults are responsible for the qualitative and quantitative alteration of the lipid and mucin components of the tear film. In addition, other contributing factors have recently been described, such as the reduction of cortisol synthesis by corneal epithelial cells. This altered condition leads to excessive macrophage activity, releasing cytokines and adhesion molecules, losing tissue homeostasis, and possibly progressing to chronic inflammation.
Conclusions: Literature evidence supports the crucial role of parainflammation and its usefulness in improving the diagnosis and treatment of DED. At the same time, further investigations are necessary to better define the transition from functional to dysfunctional parainflammation, including the role of ocular surface components other than the tear film.
Keywords: Cortisol; Dry eye disease; Dysfunctional parainflammation; Lipids; Mucins; Ocular system; Parainflammation.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: Pasquale Aragona: Consultant for AbbVie, Alcon, Alfa Intes, Bausch and Lomb, DMG, FB Vision, Fidia, Santen, SIFI, Thea, TRB-Chemedica. Stefano Barabino: consultant for Fidia, TRB-Chemedica, Alfa Intes, Alcon. Christophe Baudouin: consultant for Alcon, Glaukos, Horus Pharma, Oculis, Santen, Thea. Elisabeth M. Messmer: speaker for: Alcon/Novartis, Bausch & Lomb, Dompé, Novartis, Santen GmbH, Théa Pharma GmbH, TRB-Chemedica AG, Visufarma. Consultant for: Alcon/Novartis, Alfa Intes, DMG, Dompé, Kala, Novartis, Santen GmbH, Shire, Sun, Sifi, Théa Pharma GmbH, TRB-Chemedica AG, Visufarma. José M. Benítez-del-Castillo: consultant for Brill, GSK, Santen, Sifi, Thea, Viatris. Jutta Horwath-Winter: Speaker or consultant for: Alfa Intes, Bausch & Lomb, Icom Medical, Laboratoires Thea, Mc2 Therapeutics, Santen, Shire, TRB-Chemedica, Ursapharm. Edward Wylegala: speaker for Alcon, Baush & Lomb, Thea Santen; consultant for: Optopol Technology. Kostas Boboridis, José Salgado-Borges, Adriana Stanila and Maurizio Rolando have nothing to disclose. Ethical Approval: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Figures


Similar articles
-
Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification.Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):8642-8652. doi: 10.26355/eurrev_202009_22801. Eur Rev Med Pharmacol Sci. 2020. PMID: 32964952 Review.
-
Tear biomarkers in dry eye disease: Progress in the last decade.Indian J Ophthalmol. 2023 Apr;71(4):1190-1202. doi: 10.4103/IJO.IJO_2981_22. Indian J Ophthalmol. 2023. PMID: 37026250 Free PMC article. Review.
-
Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists.Ann Med. 2023 Dec;55(1):241-252. doi: 10.1080/07853890.2022.2157477. Ann Med. 2023. PMID: 36576348 Free PMC article. Review.
-
Management Strategies for Evaporative Dry Eye Disease and Future Perspective.Curr Eye Res. 2022 Jun;47(6):813-823. doi: 10.1080/02713683.2022.2039205. Epub 2022 May 6. Curr Eye Res. 2022. PMID: 35521685 Review.
-
Treatment of Dry Eye Disease (DED) in Asia: Strategies for Short Tear Film Breakup Time-Type DED.Pharmaceutics. 2023 Nov 5;15(11):2591. doi: 10.3390/pharmaceutics15112591. Pharmaceutics. 2023. PMID: 38004570 Free PMC article. Review.
References
-
- Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004;78:409–16. - PubMed
-
- Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013;11:246–58. - PubMed
-
- Rolando M, Barabino S. The subtle role of para-inflammation in modulating the progression of dry eye disease. Ocul Immunol Inflamm. 2021;29:811–6. - PubMed
-
- Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocular Surf. 2017;15:334–65. - PubMed
Publication types
LinkOut - more resources
Full Text Sources